|
1）Dessypris ELJ. Red cell aplasia. Wintrobeʼs Clinical Hematology, 12th edition, Greer JP, et al (editors). Philadelphia and London: Lippincott Williams & Wilkins; 2009. p.1196-211
|
|
|
|
|
2）Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007; 92: 1021-8
|
|
|
|
|
3）Hirokawa M, Sawada K, Fujishima N, et al. Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Am J Hematol. 2009; 84: 144-8
|
|
|
|
|
|
4）Verhelst D, Rossert J, Casadevall N, et al. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004; 363: 1768-71
|
|
|
|
|
|
5）Clark DA, Dessypris EN, Krantz SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood. 1984; 63: 277-86
|
|
|
|
|
|
6）Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996; 87: 3000-6
|
|
|
|
|
|
7）Krantz SB, Moore WH, Zaentz SD. Studies on red cell aplasia. V. Presence of erythroblast cytotoxicity in G-globulin fraction of plasma. J Clin Invest. 1973; 52: 324-36
|
|
|
|
|
|
8）Masuda M, Saitoh H, Mizoguchi H. Clonality of acquired primary pure red cell aplasia. Am J Hematol. 1999; 62: 193-5
|
|
|
|
|
|
9）廣川 誠．胸腺腫と腫瘍随伴症候群．検査と技術．2009; 37: 490-4
|
|
|
|
|
10）Hirokawa M, Sawada K, Fujishima N, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008; 93: 27-33
|
|
|
|
|
|
11）Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006; 135: 405-7
|
|
|
|
|
|
12）Fujishima N, Hirokawa M, Fujishima M, et al. Oligoclonal T cell expansion in blood but not in the thymus from a patient with thymoma-associated pure red cell aplasia. Haematologica. 2006; 91(12 Suppl): Ecr47
|
|
|
|
|
|
13）Masuda M, Arai Y, Okamura T, et al. Pure red cell aplasia with thymona: evidence of T-cell clonal disorder. Am J Hematol. 1997; 54: 324-8
|
|
|
|
|
|
14）Handgretinger R, Geiselhart A, Moris A, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med. 1999; 340: 278-84
|
|
|
|
|
|
15）Michishita Y, Hirokawa M, Fujishima N, et al. CDR3-independent expansion of V delta1 T lymphocytes in acquired chronic pure red cell aplasia. Immunol Lett. 2013; 150: 23-9
|
|
|
|
|
|
16）Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366: 1905-13
|
|
|
|
|
|
17）Ishida F, Matsuda K, Sekiguchi N, et al. STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 2013
|
|
|
|
|
|
18）Qiu ZY, Fan L, Wang L, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol. 2013; 6: 82
|
|
|
|
|
|
19）Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 2013; 122: 2453-9
|
|
|
|
|
|
20）Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood. 2000; 96: 1184-6
|
|
|
|
|
|
21）Song KW, Mollee P, Patterson B, et al. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002; 119: 125-7
|
|
|
|
|
|
22）Herbert KE, Prince HM, Westerman DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood. 2003; 101: 1654
|
|
|
|
|
|
23）Hirokawa M, Fukuda T, Ohashi K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013; 19: 1026-32
|
|
|
|
|
|
24）Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood. 1990; 75: 290-5
|
|
|
|
|
|
25）Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001; 98: 1687-94
|
|
|
|
|
|
26）Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142: 505-14
|
|
|
|
|
|
27）Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008; 93: 1555-9
|
|
|
|
|
|
28）Hirokawa M, Sawada K, Fujishima N, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015; 169: 879-86
|
|
|
|
|